3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
70
Neoplasms
7
Neoplasm Metastasis
5
Advanced Breast Cancer
5
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Neoplasms by Site
2
Breast Neoplasms, Male
2
Breast Diseases
2
Skin Diseases
1
Recurrence
1
Quality of Life
1
Low Grade Serous Ovarian Cancer
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Camurati-Engelmann Syndrome
1
Breast Neoplasm Female
1
Breast Cancer Metastatic
1
Breast Cancer Female
1
Bone Density
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Metastatic Breast Cancer
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Anastrozole
×
Clear all
NCT00256698
2012-08-01
FACT
AstraZeneca
Phase 3
Completed
514 enrolled
13 charts